1. Home
  2. GLPG vs INOD Comparison

GLPG vs INOD Comparison

Compare GLPG & INOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$33.03

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Innodata Inc.

INOD

Innodata Inc.

HOLD

Current Price

$52.42

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
INOD
Founded
1999
1988
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.5B
IPO Year
2005
1993

Fundamental Metrics

Financial Performance
Metric
GLPG
INOD
Price
$33.03
$52.42
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$31.33
$91.67
AVG Volume (30 Days)
87.0K
931.4K
Earning Date
02-11-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.46
EPS
N/A
1.01
Revenue
$336,643,201.00
$238,467,000.00
Revenue This Year
$1.76
$48.85
Revenue Next Year
$0.49
$25.93
P/E Ratio
N/A
$52.01
Revenue Growth
10.31
73.57
52 Week Low
$22.36
$26.41
52 Week High
$37.78
$93.85

Technical Indicators

Market Signals
Indicator
GLPG
INOD
Relative Strength Index (RSI) 62.59 43.00
Support Level $30.73 $52.11
Resistance Level $33.23 $55.18
Average True Range (ATR) 0.59 2.78
MACD 0.18 0.52
Stochastic Oscillator 91.22 40.61

Price Performance

Historical Comparison
GLPG
INOD

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About INOD Innodata Inc.

Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.

Share on Social Networks: